Current Issue

VOL 10 NO 5 • JULY 2019

This issue's cover illustration depicts the mechanism of action for carboplatin, a chemotherapy drug. The drug binds with repeating pairs of guanine causing a kink in the DNA and stopping replication. Of the platinum compounds, carboplatin has been reported to account for 0.73% of all reactions from infused chemotherapies, and up to 50% of all reactions in platinum-based chemotherapies. Artwork by Alexandra Webber Baker © 2019, DNA Illustrations, Inc., Asheville, North Carolina.


Improvements in Advance Care Planning Can Translate to Patient Comfort

Pamela Hallquist Viale, RN, MS, CNS, ANP

In our last issue, I reported on the highlights from the American Society of Clinical Oncology’s (ASCO) Annual Report on Progress Against Cancer. As noted in the report, we’ve experienced tremendous advances in the care of our patients with cancer, with an approximate 25 years of decline in the o...

Original Research

Incidence of Hypersensitivity Reactions to Carboplatin or Paclitaxel in Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer With or Without BRCA1 or BRCA2 Mutations

Andrew Garcia,(1) PharmD, Corey Frahm,(1) PharmD, Joanne M. Jeter,(2) MD, Ivo Abraham,(1) PhD, RN, Setsuko K. Chambers,(3) MD, Janiel M. Cragun,(3) MD, and Ali McBride,(1) PharmD

Many antineoplastic agents have been known to cause hypersensitivity reactions (HSRs). The incidences of HSRs are highly variable within and between all major categories of antineoplastic drugs (DeMoor et al., 2011). Of the platinum compounds, carboplatin has been reported to account for 0.73% of...

Quality Improvement

A Support Intervention for Family Caregivers of Advanced Cancer Patients

Betty Ferrell,(1) PhD, RN, MA, FAAN, FPCN, CHPN, Kate Kravits,(1) MA, RN, HNB-BS, LPC, NCC, ATR-BC, Tami Borneman,(1) RN, MSN, CNS, FPCN, Sumanta K. Pal,(1) MD, and Janet Lee,(2) EdM

Advanced practitioners (APs) in oncology spend significant time communicating with and supporting family caregivers. The family caregiver’s role has become increasingly important as cancer care has shifted from inpatient to home-based care. Family caregivers are the primary providers of cancer ca...

Quality Improvement

The Integration of Survivorship Care Planning at a Comprehensive Cancer Center

Elizabeth B. McGrath, DNP, APRN, AGACNP-BC, AOCNP®, ACHPN, Anna Schaal, MSN, APRN, and Claire Pace, MSN, APRN

The number of patients surviving a cancer diagnosis continues to increase. Cancer survivorship reached nearly 15.5 million people in 2014, and this is projected to increase to over 20 million by 2026 (National Cancer Institute, 2016). Although improved survival is an exciting and much desired out...

Review Article

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach

Yi L. Hwa, DNP,(1) Teresa Fogaren, MSN, AGNP-C,(2) Allison Sams, AGPCNP-BC,(3) Douglas V. Faller, MD, PhD,(4) Dawn M. Stull, PharmD, BCOP,(5) Sara Thuenemann, RN, MSN, DHSc,(6) and Lisa Mendelson, MSN, AGPCNP-BC(7)

Systemic immunoglobulin light-chain (AL) amyloidosis is caused by plasma cell clones in the bone marrow (median 7%–10% marrow infiltration) that produce insoluble, misfolded immunoglobulin light chain proteins, which are deposited in various tissues and organs as amyloid fibrils leading to progre...

Grand Rounds

Therapy Management Using Modified 2-Weeks-On/1-Week-Off Dosing Schedule in Patients With Metastatic Renal Cell Carcinoma Receiving Sunitinib: A Hypothetical, Illustrative Case Scenario

Kimberly D. Allman,(1) CNP, Joanne C. Ryan,(2) PhD, RN, Andrew Clair,(2) PhD, and Sarah Yenser-Wood,(3) NP

An estimated 73,820 patients in the United States will be diagnosed with renal cell carcinoma (RCC) in 2019 (National Cancer Institute, 2019), and up to 40% of RCC patients will eventually experience progression to metastatic disease (Ferlay et al., 2015; Znaor Lortet-Tieulent, Laversanne, Jemal,...

Prescriber's Corner

Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia

Shelby L. Merchant, PharmD, Kathryn Culos, PharmD, BCOP, and Houston Wyatt, PharmD, CSP

Acute myeloid leukemia (AML) is a hematologic malignancy originating from abnormal proliferation of immature hematopoietic cells in the bone marrow. Patient age, performance status, molecular markers, and cytogenetics determine risk stratification and prognosis. Approximately two thirds of patien...

Prescriber's Corner

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Urvi J. Patel, PharmD, MPH, and Sarah Caulfield, PharmD, BCOP

Prostate cancer is a male-specific oncologic disease that is one of the top four leading causes of cancer in the United States, which is evidenced by an incidence rate of 9.9% of all new cancer cases in 2019 (National Cancer Institute, 2019). It is the most commonly diagnosed cancer in males, wit...

Section Seperator
Section Seperator
Section Seperator
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.